Sanofi's heart disease therapy DuoPlavin gets EU drug regulator's nod for expanded approval

Nov. 11, 2022 7:04 AM ETSanofi (SNY)By: Ravikash, SA News Editor

Blue glass European building architecture with Sanofi logo Berlin


  • A committee of the European Medicines Agency (EMA) recommended the expanded approval of Sanofi's (NASDAQ:SNY) heart disease drug DuoPlavin.
  • The active substance in DuoPlavin is clopidogrel and acetylsalicylic acid.
  • The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a change

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.